Topicalcorticosteroid withdrawal is a rare rebound reaction in patients with topical steroid overuse that occurs after discontinuation.
This is usually caused by prolonged use of moderate to high strength topical corticosteroids. Withdrawal may present with skin burning, itching, redness, scaling, swelling, papules, or pustules.
Redness and swelling of the lids - steroid withdrawal after prolonged potent steroid use on the face.
Redness and swelling of the forearm after abrupt discontinuation of prolonged potent topical steroid use. Palms are not affected (red sleeve sign).
Who gets topical corticosteroid withdrawal?
The prevalence of topical corticosteroid withdrawal reactions is unknown.
Major risk factors for topical steroid withdrawal include:
Topical corticosteroid of medium (69%) or high (21%) potency
Topical corticosteroid treatment duration of 6 months or more (63%).
What causes topical corticosteroid withdrawal?
The following mechanisms may explain the pathogenesis of topical steroid withdrawal:
Tachyphylaxis (reduced response) with continued application, leading to usage of higher doses
Upregulation of glucocorticoidreceptor b in atopic dermatitis patients with poor response to topical steroids
Keratinocytes have continued suppression of self-cortisol production after topical steroid cessation
Topical corticosteroids cause vasoconstriction, but on withdrawal rebound vasodilation occurs from increased nitric oxide release, leading to skin erythema
Barrier disruption induces a rebound cytokine cascade once the anti-inflammatory effects from topical corticosteroids are withdrawn
Elevated NAD+ oxidation of mitochondrial complex 1 and conversion of tryptophan into kynurenine metabolites and nicotinic acid.
What are the clinical features of topical corticosteroid withdrawal?
Prior to stopping the steroid, the skin often appears normal or near-normal, although patients with atopic dermatitis may have itching or prurigo-like nodules. The onset of withdrawal from the time of discontinuation ranges from 48 hours to over 3 months.
Withdrawal typically occurs in four stages.
A few days (usually) after discontinuation, there is an acuteeruption of burning red, exudative skin which may extend to untreated areas.
Skin becomes dry and itchy with shedding (desquamation).
Skin starts to recover but has increased sensitivity and intermittent flares may occur.
Skin recovers to the state prior to topical corticosteroid cessation. The recovery process may take weeks to years.
Erythematoedematous subtype: commonly seen in patients with chronicatopicdermatitis, characterised by burning sensation, erythema, oedema, and scaling.
Papulopustular subtype: commonly seen after steroid use for pigmentation changes or other cosmetic reasons, characterised by papules, pustules, and erythema. This subtype is less commonly affected by burning, stinging, or swelling.
How do clinical features vary in differing types of skin?
Darker or grey skin changes, rather than redness, may feature in more pigmentedskin types.
What are the complications of topical corticosteroid withdrawal?
Intense itching and sleep disturbance.
Flare of pre-treatment skin disorder, particularly atopic dermatitis.
Swelling (oedema), especially of the eyelids or ankles
‘Elephant wrinkles’ of the posterior elbows and anterior knees (extensors)
Red sleeve sign.
One of the challenges is determining whether the skin reaction observed is due to the stopping of topical corticosteroids, or a worsening of the underlying skin disease for which the steroids were prescribed.
Patch testing can be useful in excluding contact dermatitis to the topical corticosteroid or creamexcipients, or other topical agents (eg, emollients), although this may be difficult if there are insufficient areas of normal skin.
Histology is not useful in the diagnosis of topical corticosteroid withdrawal due to its non-specific histological features of epidermalatrophy, spongiosis, and parakeratosis.
What is the differential diagnosis for topical corticosteroid withdrawal?
How do you prevent topical corticosteroid withdrawal?
Reduce the frequency and potency of topical corticosteroid use as soon as inflammatory skin disorders clear (avoid ongoing daily use ‘to prevent recurrence’).
Avoid continued use of moderate to potent topical corticosteroids on the face.
Minimise continuous prolonged corticosteroid treatment duration eg, over 2 weeks. Some conditions such as vulval lichen sclerosus may need more than 4 weeks therapy to maximise beneficial response.
Reduce topical steroid potency and application from daily to twice weekly after 2–4 weeks of use.
Concerns about the risk of topical corticosteroid withdrawal should not prevent adequate treatment of atopic dermatitis and other skin conditions, as far more people respond to appropriate topical steroid use than develop withdrawal.
What is the outcome for topical corticosteroid withdrawal?
There are currently no specific treatments that clearly reduce the time to resolution, which can range from 72 hours to months, with the majority (77%) recovering after 3 months.
Topical corticosteroid withdrawal can have a prolonged course of up to 5 years after cessation in a small minority of patients.
Fukaya M, Sato K, Sato M, et al. Topical steroid addiction in atopic dermatitis. Drug Healthc Patient Saf. 2014;6:131–8. doi: 10.2147/dhps.s6920. Journal
Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541–549.e2. doi: 10.1016/j.jaad.2014.11.024. Journal
Hwang J, Lio PA. Topical corticosteroid withdrawal (‘steroid addiction’): an update of a systematic review. J Dermatolog Treat. 2022;33(3):1293–8. doi: 10.1080/09546634.2021.1882659. Journal
Sheary B. Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use. Dermatitis. 2018;29(4):213–8. doi: 10.1097/DER.0000000000000387. Journal
Shobnam N, Ratley G, Saksena S et al. - Topical steroid withdrawal is a targetable overproduction of nicotinic acid from mitochondrial complex I overexpression. BJD Volume 191, Issue Supplement 2, August 2024. Journal
Sheary B. Topical corticosteroid addiction and withdrawal – An overview for GPs. Aust Fam Physician. 2016;45(6):386–8. Journal
Tan SY, Chandran NS, Choi ECE. Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety, Addiction and Withdrawal. Clin Drug Investig. 2021;41(10):835–42. doi: 10.1007/s40261-021-01072-z. Journal